Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Januar 2015 07:30 ET | Quelle: Advaxis

Advaxis Submits Investigational New Drug Application to FDA for ADXS-HER2

PRINCETON, N.J., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it submitted an...
30. Dezember 2014 07:30 ET | Quelle: Advaxis

Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday Housecall

PRINCETON, N.J., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that its Lm-LLO immunotherapy technology was...
19. Dezember 2014 15:34 ET | Quelle: Advaxis

Advaxis Completes $17 Million Financing

PRINCETON, N.J., Dec. 19, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it has executed...
15. Dezember 2014 07:30 ET | Quelle: Advaxis

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers

PRINCETON, N.J., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug...
12. Dezember 2014 07:30 ET | Quelle: Advaxis

Advaxis's Cancer Immunotherapies Featured on FOX News

PRINCETON, N.J., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that its Lm-LLO immunotherapy technology is...
11. Dezember 2014 07:30 ET | Quelle: Advaxis

Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology

PRINCETON, N.J., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its Lm-LLO immunotherapy...
08. Dezember 2014 07:30 ET | Quelle: Advaxis

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer

PRINCETON, N.J., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug...
25. November 2014 07:30 ET | Quelle: Advaxis

Advaxis to Present at the LD Micro Conference

PRINCETON, N.J., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the LD...
20. November 2014 07:30 ET | Quelle: Advaxis

Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program

PRINCETON, N.J., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced it has received preliminary...
12. November 2014 07:30 ET | Quelle: Advaxis

Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer

PRINCETON, N.J., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted...

Vorherige Seite

Nächste Seite